A live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33496263.
- Also identified by DOI 10.7554/eLife.64166 and PMC identifier 7837694.
- Licence recorded as CC0.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Leptospirosis is the leading zoonotic disease in terms of morbidity and mortality worldwide. Effective prevention is urgently needed as the drivers of disease transmission continue to intensify. The key challenge has been developing a widely applicable vaccine that protects against the >300 serovars that can cause leptospirosis. Live attenuated mutants are enticing vaccine candidates and poorly explored in the field. We evaluated a recently characterized motility-deficient mutant lacking the expression of a flagellar protein, FcpA. Although the <i>fcpA<sup>-</sup></i> mutant has lost its ability to cause disease, transient bacteremia was observed. In two animal models, immunization with a single dose of the <i>fcpA<sup>-</sup></i> mutant was sufficient to induce a robust anti-protein antibodies response that promoted protection against infection with different pathogenic Leptospira species. Furthermore, characterization of the immune response identified a small repertoire of biologically relevant proteins that are highly conserved among pathogenic Leptospira species and potential correlates of cross-protective immunity.
Medical subject headings
- Bacterial Vaccines
- Cross Protection
- Leptospira interrogans
- Leptospirosis
- Vaccines, Attenuated